Biomarkers
Companion Diagnostics | Disease Progression | Therapeutic Success
GenXPro GmbH is a pioneer in advanced biomarker discovery, specializing in ultra-sensitive detection and analysis of cell-free nucleic acids. From small RNA and miRNA to cfRNA, cfDNA methylation patterns, and cfDNA mutations, GenXPro’s technologies support highly accurate liquid biopsy analyses for a broad range of research and clinical applications.
Biomarkers based on cfRNA, cfDNA & methylation
We are profiling mRNA, smallRNA (microRNA), non-coding RNA, DNA, methylation of the DNA (epigenetics) and examine specific characteristics of them for high-resolution biomarker identification. Based on the findings, qPCR- or other single- or multigene assays are developed for cost-efficient biomarker analyses.
Precision in Small RNA, miRNA, and cfRNA Analysis
GenXPro’s TrueQuant technology eliminates PCR-induced bias and captures small RNA species — including miRNAs, piRNAs, and other non-coding RNAs — with unmatched sensitivity. Even minute inputs, such as a few microliters of plasma, can be profiled with single-tube protocols that preserve rare biomarker signatures, making GenXPro’s smallRNA and cfRNA workflows ideal for non-invasive liquid biopsy testing.
Our proven expertise in these highly sensitive workflows has enabled successful biomarker discovery across a broad spectrum of diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. Researchers and clinicians trust GenXPro’s solutions to reveal novel biomarkers that support early detection, improve prognostic accuracy, and guide personalized treatment decisions. By delivering robust data from precious and limited specimens, GenXPro empowers breakthrough research that is shaping the future of diagnostics and precision medicine.
Cutting-Edge cfDNA Methylation and Mutation Analyses
Beyond RNA, GenXPro offers comprehensive cfDNA solutions. Our expertise extends to methylation analysis — a powerful biomarker for cancer and other diseases — enabling genome-wide mapping of epigenetic signatures to detect early-stage cancers or monitor therapy response.
In addition, GenXPro’s high-sensitivity cfDNA mutation detection assays pinpoint single-nucleotide variants and other genomic alterations with robust error-correction strategies, even from ultra-low DNA inputs. These advanced techniques make GenXPro’s cfDNA portfolio ideal for early diagnosis, relapse monitoring, and personalized medicine.
Integrated Multi-Omics for Personalized Health
With its focus on both cfDNA and cfRNA, we provide a holistic molecular profile for every sample. This multi-omic integration — combining epigenetic, genetic, and transcriptomic signatures — empowers the discovery of novel biomarkers and an may support the development of highly personalized therapies.
Additionally, our experienced bioinformatics team guides data analysis and interpretation, delivering actionable results that drive progress in diagnostics, drug discovery, and precision oncology.
